Karen A.  Foster net worth and biography

Karen Foster Biography and Net Worth

Insider of BioLife Solutions
Karen Foster has been chief quality officer at BioLife since December 2019. She joined the company as Vice President of Operations in April 2016. From 2003 to early 2016, Karen was Vice President of Laboratory Operations and Site Leader at ViaCord, LLC, a family cord blood bank, and subsidiary of PerkinElmer Inc.

Karen has managed manufacturing and quality operations in several capacities over the course of her 25-year career, for such companies as Pfizer, Inc. (formerly Pharmacia Corporation) and Amersham Pharmacia Biotech, Inc. (formerly Pharmacia Biotech, Inc.)

She has two degrees from the University of Wisconsin, Milwaukee:  an MBA specializing in Operations Management, and an MS in Zoology. She earned her B.S. in Biological Sciences from Michigan Technological University.

What is Karen A. Foster's net worth?

The estimated net worth of Karen A. Foster is at least $2.74 million as of March 27th, 2024. Ms. Foster owns 159,145 shares of BioLife Solutions stock worth more than $2,735,703 as of April 25th. This net worth approximation does not reflect any other assets that Ms. Foster may own. Additionally, Ms. Foster receives an annual salary of $395,200.00 as Insider at BioLife Solutions. Learn More about Karen A. Foster's net worth.

How old is Karen A. Foster?

Ms. Foster is currently 64 years old. There are 6 older executives and no younger executives at BioLife Solutions. Learn More on Karen A. Foster's age.

What is Karen A. Foster's salary?

As the Insider of BioLife Solutions, Inc., Ms. Foster earns $395,200.00 per year. There are 4 executives that earn more than Ms. Foster. The highest earning executive at BioLife Solutions is Mr. Roderick de Greef, CEO & Chairman, who commands a salary of $1,630,000.00 per year. Learn More on Karen A. Foster's salary.

How do I contact Karen A. Foster?

The corporate mailing address for Ms. Foster and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at [email protected]. Learn More on Karen A. Foster's contact information.

Has Karen A. Foster been buying or selling shares of BioLife Solutions?

Karen A. Foster has not been actively trading shares of BioLife Solutions during the last ninety days. Most recently, Karen A. Foster sold 395 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $17.99, for a transaction totalling $7,106.05. Following the completion of the sale, the insider now directly owns 159,145 shares of the company's stock, valued at $2,863,018.55. Learn More on Karen A. Foster's trading history.

Who are BioLife Solutions' active insiders?

BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.

Are insiders buying or selling shares of BioLife Solutions?

In the last twelve months, BioLife Solutions insiders bought shares 5 times. They purchased a total of 1,055,603 shares worth more than $12,648,274.13. In the last twelve months, insiders at the medical equipment provider sold shares 88 times. They sold a total of 203,083 shares worth more than $3,138,630.18. The most recent insider tranaction occured on April, 22nd when insider Sarah Aebersold sold 410 shares worth more than $6,765.00. Insiders at BioLife Solutions own 2.7% of the company. Learn More about insider trades at BioLife Solutions.

Information on this page was last updated on 4/22/2024.

Karen A. Foster Insider Trading History at BioLife Solutions

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/27/2024Sell395$17.99$7,106.05159,145View SEC Filing Icon  
3/11/2024Sell319$17.42$5,556.98164,717View SEC Filing Icon  
1/19/2024Sell1,198$16.76$20,078.48124,027View SEC Filing Icon  
1/2/2024Sell601$16.75$10,066.75125,225View SEC Filing Icon  
12/1/2023Sell466$12.37$5,764.42125,340View SEC Filing Icon  
11/13/2023Sell114$10.77$1,227.78125,539View SEC Filing Icon  
9/28/2023Sell568$14.16$8,042.88124,767View SEC Filing Icon  
8/25/2023Sell410$10.99$4,505.90124,342View SEC Filing Icon  
8/14/2023Sell156$12.38$1,931.28124,752View SEC Filing Icon  
6/27/2023Sell590$22.91$13,516.90124,908View SEC Filing Icon  
5/31/2023Sell392$23.21$9,098.32125,498View SEC Filing Icon  
5/15/2023Sell106$18.71$1,983.26125,890View SEC Filing Icon  
4/6/2023Sell1,101$20.03$22,053.03121,839View SEC Filing Icon  
3/29/2023Sell390$20.62$8,041.80122,940View SEC Filing Icon  
3/7/2023Sell175$22.95$4,016.25123,330View SEC Filing Icon  
3/1/2023Sell1,203$22.75$27,368.25123,505View SEC Filing Icon  
2/9/2023Sell81$24.60$1,992.60124,708View SEC Filing Icon  
12/28/2022Sell605$16.90$10,224.50107,811View SEC Filing Icon  
11/29/2022Sell307$19.93$6,118.51108,416View SEC Filing Icon  
11/10/2022Sell91$23.16$2,107.56108,723View SEC Filing Icon  
9/29/2022Sell559$23.02$12,868.18108,814View SEC Filing Icon  
8/10/2022Sell95$23.17$2,201.15109,394View SEC Filing Icon  
6/28/2022Sell598$14.86$8,886.28108,236View SEC Filing Icon  
5/27/2022Sell174$14.53$2,528.22107,839View SEC Filing Icon  
5/13/2022Sell58$12.32$714.56107,480View SEC Filing Icon  
4/18/2022Sell16,413$17.59$288,704.67107,538View SEC Filing Icon  
3/29/2022Sell547$22.24$12,165.28View SEC Filing Icon  
3/1/2022Sell221$23.78$5,255.38View SEC Filing Icon  
2/10/2022Sell293$29.38$8,608.34View SEC Filing Icon  
12/29/2021Sell625$39.37$24,606.25View SEC Filing Icon  
11/30/2021Sell315$37.59$11,840.85View SEC Filing Icon  
11/22/2021Sell16,332$46.19$754,375.08View SEC Filing Icon  
10/25/2021Sell16,332$44.45$725,957.40View SEC Filing Icon  
10/14/2021Sell1,082$39.97$43,247.54View SEC Filing Icon  
9/27/2021Sell16,332$44.66$729,387.12View SEC Filing Icon  
8/26/2021Sell325$57.26$18,609.5072,452View SEC Filing Icon  
8/23/2021Sell16,332$46.54$760,091.28View SEC Filing Icon  
7/26/2021Sell16,333$45.24$738,904.92View SEC Filing Icon  
6/21/2021Sell16,332$42.79$698,846.2889,716View SEC Filing Icon  
5/28/2021Sell264$33.87$8,941.6873,384View SEC Filing Icon  
5/24/2021Sell16,332$31.44$513,478.0889,980View SEC Filing Icon  
4/19/2021Sell16,332$32.58$532,096.5689,980View SEC Filing Icon  
4/1/2021Sell3,414$36.53$124,713.4274,208View SEC Filing Icon  
3/26/2021Sell2,562$35.01$89,695.6265,411View SEC Filing Icon  
3/22/2021Sell16,332$37.56$613,429.9284,305View SEC Filing Icon  
2/26/2021Sell284$39.57$11,237.8867,973View SEC Filing Icon  
2/22/2021Sell16,334$39.66$647,806.4484,591View SEC Filing Icon  
2/19/2021Sell3,344$40.76$136,301.4454,899View SEC Filing Icon  
2/17/2021Sell3,281$41.55$136,325.5554,899View SEC Filing Icon  
12/1/2020Sell166$35.49$5,891.3450,742View SEC Filing Icon  
9/29/2020Sell977$28.63$27,971.5150,908View SEC Filing Icon  
8/26/2020Sell179$20.48$3,665.9251,885View SEC Filing Icon  
5/28/2020Sell170$16.87$2,867.9052,064View SEC Filing Icon  
2/26/2020Sell884$15.02$13,277.6823,701View SEC Filing Icon  
See Full Table

Karen A. Foster Buying and Selling Activity at BioLife Solutions

This chart shows Karen A Foster's buying and selling at BioLife Solutions by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioLife Solutions Company Overview

BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $16.86
Low: $16.12
High: $17.12

50 Day Range

MA: $17.38
Low: $15.14
High: $18.80

2 Week Range

Now: $16.86
Low: $8.92
High: $24.50

Volume

400,851 shs

Average Volume

411,223 shs

Market Capitalization

$763.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67